MeSH D020326 - migraine without aura
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| AbbVie | Ubrogepant | Ubrelvy | 2031-11-10 | 2019-12-23 | $866 M | Q2/23-Q1/24 |
| Eli Lilly | Lasmiditan | Rayvow | 2022-08-17 | |||
| Lasmiditan | Reyvow | 2023-03-27 | 2020-01-31 | |||
| Pfizer | Rimegepant | Vydura | 2022-04-25 | $928 M | Y2023 | |
| Rimegepant | Nurtec | 2030-03-09 | 2020-02-27 |
Clinical Trials
Historical Success Rate
Phase 1
100%2/2
Phase 2
50%3/6
Phase 3
30%7/23
Approved: 3Overall Success rate: 15%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use